TrialESMO open2023

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.

B C Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.